Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.68 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416620 | 0.90 | SMN1; SMN2 (0.77) | SAE1UBA2HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL29703055 | 0.90 | SMN1; SMN2 (0.77) | SAE1UBA2HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL13680542 | 0.90 | CNR1 (0.68) | SAE1UBA2HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL31054278 | 0.85 | SMN1; SMN2 (0.75) | SAE1UBA2HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL259602 | 0.85 | SMN1; SMN2 (0.75) | SAE1UBA2HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL9036479 | 0.83 | HSD17B10 (0.65) | SAE1UBA2HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL5852140 | 0.83 | SAE1 (0.76) | SAE1UBA2HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL16488795 | 0.82 | MEN1 (0.51) | SAE1UBA2HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL21567990 | 0.82 | HSD17B10 (0.74) | SAE1UBA2HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL30762995 | 0.82 | HSD17B10 (0.74) | SAE1UBA2HSD17B10SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017762-A1 | INK JET INK FOR FORMING AN INFRARED ABSORBING IMAGE, INFRARED ABSORBING IMAGE FORMING METHOD, AND RECORDED MATERIAL | FUJIFILM CORPORATION (JP) | 2022-01-20 | — | — | US | disclosed |
| US-10556904-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10351522-B2 | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2019-07-16 | — | — | US | disclosed |
| US-20190194191-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-3502198-A1 | INK FOR INK JET RECORDING, INK JET RECORDING METHOD, INFRARED READING METHOD, AND PRINTED PRODUCT | FUJIFILM Corporation (JP) | 2019-06-26 | — | — | EP | disclosed |
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2018-06-28 | — | — | US | disclosed |
| EP-2183254-B1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2017-06-21 | — | — | EP | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1878727-A1 | 2-AMINOQUINAZOLINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-7205291-B2 | High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-7157580-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157580-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2007-01-02 | — | — | US | disclosed |
| CN-1827595-A | Naphthurea composition for preparation of carrier generation materials and process for preparing same | UNIV TIANJIN (CN) | 2006-09-06 | — | — | CN | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| US-5614498-A | OLIGOPEPTIDES, BRONCHDILATORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5496928-A | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0555537-A2 | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | HCRTR2, HCRTR1, NPSR1 | SAE1 1360/4885UBA2 1287/4885HSD17B10 1326/4885 |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | SAE1 2263/4885UBA2 1751/4885HSD17B10 1365/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | SAE1 1690/4885UBA2 922/4885HSD17B10 440/4885 |
| US-10556904-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | SAE1 2685/4885UBA2 2447/4885HSD17B10 415/4885 |
| US-10351522-B2 | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | HCRTR2, HCRTR1, NPSR1 | SAE1 1360/4885UBA2 1287/4885HSD17B10 1326/4885 |
| US-20190194191-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | SAE1 2685/4885UBA2 2447/4885HSD17B10 415/4885 |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | SAE1 1830/4885UBA2 3123/4885HSD17B10 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.